Comparison of the discriminative and neuroendocrine effects of centrally penetrating κ-opioid agonists in rhesus monkeys

Psychopharmacology

Volumn 164, Issue 1, 2002, Pages 115-120

  Butelman, Eduardo R ^a   Ball, Jonathan W ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Opioids; Biomarker; Drug discrimination; Prolactin

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; BREMAZOCINE; FENTANYL; KAPPA OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALBUPHINE; NALMEFENE; PROLACTIN; R 84760; SPIRADOLINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG POTENCY; FEMALE; FOOD; LEARNING; MALE; NEUROENDOCRINOLOGY; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; REINFORCEMENT; RHESUS MONKEY; TASK PERFORMANCE;

ANIMALS; BENZENEACETAMIDES; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MACACA MULATTA; NEUROSECRETORY SYSTEMS; PROLACTIN; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA;

EID: 0036402146     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1195-y     Document Type: Article

References (41)

1. Bero LA, Lurie SN, Kuhn CM (1987) Early ontogeny of kappa-opioid receptor regulation of prolactin secretion in the rat. Brain Res 465:189-196
2. Bowen CA, Negus SS, Kelly M, Mello NK (2002) The effects of heroin on prolactin levels in male rhesus monkeys: use of cumulative dosing procedures. Psychoneuroendocrinology 27:319-336
3. Brandt MR, Negus SS, Mello NK, Furness MS, Zhang X, Rice KC (1999) Discriminative stimulus effects of the nonpeptidic delta-opioid agonist SNC80 in rhesus monkeys. J Pharmacol Exp Ther 290:1157-1164
4. Butelman ER, Harris TJ, Kreek M (1999) Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur J Pharmacol 383:305-309
5. Butelman ER, Ko MC, Traynor JR, Vivian JA, Kreek MJ, Woods JH (2001) GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys. J Pharmacol Exp Ther 298:1049-1059
6. Carey GJ, Bergman J (2001) Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists. J Pharmacol Exp Ther 297:215-223
7. Chen ACH, LaForge KS, Ho A, McHugh PF, Kellogg S, Bell K, Schluger R, Leal SM, Kreek MJ (2002) Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet (Neuropsychiatr Genet) 114:429-435
8. Daunais JB, McGinty JF (1995) Cocaine binges differentially alter striatal preprodynorphin and zif/268 mRNAs. Brain Res Mol Brain Res 29:201-210
9. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M (1996) International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48:567-592
10. Di Chiara G, Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067-1080
11. Dougherty TB, Porche VH, Thall PF (2000) Maximum tolerated dose of nalmefene in patients receiving epidural fentanyl and dilute bupivacaine for postoperative analgesia. Anesthesiology 92:1010-1016
12. Dykstra LA, Gmerek DE, Winger G, Woods JH (1987a) Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and beta-funaltrexamine. J Pharmacol Exp Ther 242:421-427
13. Dykstra LA, Gmerek DE, Winger G, Woods JH (1987b) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 242:413-420
14. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637
15. France CP, Gerak LR (1994) Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J Pharmacol Exp Ther 270:992-999
16. France CP, Morse WH (1989) Pharmacological characterization of supersensitivity to naltrexone in squirrel monkeys. J Pharmacol Exp Ther 250:937-943
17. France CP, Medzihradsky F, Woods JH (1994) Comparison of kappa opioids in rhesus monkeys: behavioral effects and receptor binding affinities. J Pharmacol Exp Ther 268:47-58
18. Fujibayashi K, Sakamoto K, Watanabe M, Iizuka Y (1994) Pharmacological properties of R-84760, a novel kappa-opioid receptor agonist. Eur J Pharmacol 261:133-140
19. Heidbreder CA, Goldberg SR, Shippenberg TS (1993) The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res 616:335-338
20. Hoehe M, Duka T, Doenicke A (1988) Human studies on the mu opiate receptor agonist fentanyl: neuroendocrine and behavioral responses. Psychoneuroendocrinology 13:397-408
21. 2-receptor deficient mice. Neuron 19:103-113
22. Kenakin T (1993) Pharmacologic analysis of drug receptor interaction, 2nd edn. Raven Press, New York
23. Kobayashi N, Naganuma H (1999) Quantitative analysis of R-84760, a selective kappa-opioid receptor agonist, in plasma by liquid chromatography with electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal 19:829-836
24. LaForge KS, Yuferov V, Kreek MJ (2000) Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol 410:249-268
25. Mello NK, Mendelson JH, Kelly M (2000) Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys. Pharmacol Biochem Behav 66:275-283
26. Merchenthaler I (1991) Neurons with access to the general circulation in the central nervous system of the rat: a retrograde tracing study with fluoro-gold. Neuroscience 44:655-662
27. Moore KE, Lookingland KJ (1995) Dopaminergic neuronal systems in the hypothalamus. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 245-256
28. Negus SS, Burke TF, Medzihradsky F, Woods JH (1993) Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine. J Pharmacol Exp Ther 267:896-903
29. NIH Definitions Working Group (2000) Biomarkers and surrogate endpoints in clinical research: definitions and conceptual model. In: Downing GJ (ed) Biomarkers and surrogate endpoints: clinical research and applications. Elsevier, Amsterdam
30. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986a) Psychotomimesis mediated by kappa opiate receptors. Science 233:774-776
31. Pfeiffer A, Braun S, Mann K, Meyer HD, Brantl V (1986b) Anterior pituitary hormone responses to a kappa-opioid agonist in man. J Clin Endocrinol Metab 62:181-185
32. Preston KL, Bigelow GE (1994) Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure. J Pharmacol Exp Ther 271:48-60
33. Rimoy GH, Wright DM, Bhaskar NK, Rubin PC (1994) The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist. Eur J Clin Pharmacol 46:203-207
34. Seymour RA, Stassen L, Moore U, Hawkesford JE, Oshima T, Suggi M, Nimmo WS (2000) A double blind, placebo controlled study of the tolerability and efficacy of a new kappa-opioid receptor agonist (R-84760) in patients with pain after dental surgery. Clin Drug Invest 20:409-414
35. Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89:2046-2050
36. Staley JK, Rothman RB, Rice KC, Partilla J, Mash DC (1997) Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neurosci 17:8225-8233
37. Szmuszkovicz J (1999) U50,488 and the kappa-receptor: a personalized account covering 1973 to 1990. In: Jucker E (ed) Progress in drug research. Birkhauser, Basel, pp 168-195
38. Unterwald EM, Kreek MJ, Cuntapay M (2001) The frequency of cocaine administration impacts cocaine-induced receptor alterations. Brain Res 900:103-109
39. Ur E, Wright DM, Bouloux PM, Grossman A (1997) The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol 120:781-784
40. Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157:151-162
41. Wang DS, Sternbach G, Varon J (1998) Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. J Emerg Med 16:471-475